All questions are shown as received by the Trust.
Q1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
a. ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)
b. Amivantamab
c. Atezolizumab Monotherapy
d. Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
e. Atezolizumab subcutaneous
f. Dabrafenib + Trametinib
g. Docetaxel monotherapy or in combination with Carboplatin/Cisplatin
h. Durvalumab
i. Gemcitabine
j. Nintedanib + Docetaxel
k. Nivolumab
l. Osimertinib
m. Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)
n. Paclitaxel
o. Pembrolizumab Monotherapy
p. Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
q. Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)
r. Pemetrexed + Platinum (Carboplatin/Cisplatin)
s. RET Inhibitors (Pralsetinib, Selpercatinib)
t. Sotorasib
u. Tepotinib
v. Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
w. Other active systemic anti-cancer therapy
x. Palliative care only
Q2. How many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY in the past 3 months with:
a. Atezolizumab monotherapy
b. Durvalumab
c. Gemcitabine
d. Nivolumab
e. Osimertinib
f. Pembrolizumab Monotherapy
g. Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
h. Paclitaxel
i. Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
j. Other active systemic anti-cancer therapy (SACT)
k. Palliative care only
